<DOC>
	<DOCNO>NCT01268033</DOCNO>
	<brief_summary>Background Idiopathic nephrotic syndrome rare disease begin childhood treat immunosuppressant ( i.e . steroid , mycophenolate mofetil , cyclophosphamide , cyclosporine ) . Renal function patient suffer severe , steroid-dependent nephrotic syndrome failure toxic side effect immunosuppressant treatment major matter concern . Cyclosporine endanger renal parenchyma ( fibrosis ) patient must take treatment year . At time , low dos cyclosporine allow proteinuria reappear , provokes degradation renal function focal segmental glomerulosclerosis . Some recent data lead conclusion Rituximab may effective disease , cyclosporin spar effect . Purpose The aim study evaluate efficacy Rituximab versus placebo treatment pediatric patient suffer severe cyclosporine-dependent nephrotic syndrome . Abstract Patients include study period remission proteinuria . Two infusion Rituximab - dose 375 mg/mÂ²- placebo administer one week interval . Other immunosuppressant treatment gradually taper taper pattern group . In case relapse nephrotic syndrome , blind code broken . Rituximab infuse patient receive placebo .</brief_summary>
	<brief_title>Efficacy Rituximab For Treatment Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood</brief_title>
	<detailed_description>After infusion Rituximab placebo , patient examine nephrologist monthly basis five month . Follow focus proteinuria , albuminemia , lymphocyte phenotyping Rituximab pharmacokinetics</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Nephrosis , Lipoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Male Female patient 2 18 year , idiopathic nephrotic syndrome ( NS ) Steroid Sensitive Nephrotic Syndrome ( accord French pediatric protocol ) . NEPHRUTIX Calcineurin inhibitor Dependent NS NS anticalcineurin treatment effective . Others immunosuppressive treatment ( MMF ) must fail control disease activity . Effective contraception girl childbearing age . The patient able understand sign write informed consent OR parent legal guardian able understand sign write informed consent , must obtain prior initiation study procedure Terminal renal failure require dialysis/transplantation Transcutaneous oxygen stauration &lt; 97 % Clinical Radiological brochopulmonar pleural abnormality Asymptomatic carrier Hepatitis B virus history Hepatitis B Contraindication Rituximab ( RTX ) Parents/patient refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>rituximab</keyword>
	<keyword>idiopathic nephrotic syndrome</keyword>
	<keyword>minimal change disease</keyword>
	<keyword>focal segmental glomerulosclerosis</keyword>
</DOC>